UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Breast (Edinburgh), 2022-12, Vol.66, p.169-177

2022

Link zum Volltext

Verfügbarkeit prüfen

Role of Immunotherapy in Breast Cancer

JCO oncology practice, 2023-04, Vol.19 (4), p.167-179

2023

Link zum Volltext

Verfügbarkeit prüfen

775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A872-A872

2023

Link zum Volltext

Verfügbarkeit prüfen

Better Reporting Needed for Cosmetics and Women’s Health

American journal of obstetrics and gynecology, 2018-02, Vol.218 (2), p.265-266

2018

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer

Breast cancer research and treatment, 2021-06, Vol.187 (2), p.397-405

2021

Link zum Volltext

Verfügbarkeit prüfen

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy

Heliyon, 2020-05, Vol.6 (5), p.e03841, Article e03841

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9595-TPS9595

2023

Link zum Volltext

Verfügbarkeit prüfen

Landscape of circulating tumour DNA in metastatic breast cancer

EBioMedicine, 2020-08, Vol.58, p.102914-102914, Article 102914

2020

Link zum Volltext

Verfügbarkeit prüfen

Lung Cancer Survival in Patients With Autoimmune Disease

JAMA network open, 2020-12, Vol.3 (12), p.e2029917-e2029917

2020

Link zum Volltext

Verfügbarkeit prüfen

Visual perception training: a prospective cohort trial of a novel, technology-based method to teach melanoma recognition

Postgraduate medical journal, 2019-06, Vol.95 (1124), p.350

2019

Link zum Volltext

Verfügbarkeit prüfen

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration

JNCI cancer spectrum, 2018-04, Vol.2 (2), p.pky012-pky012

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response

BJC Reports, 2024-06, Vol.2 (1), p.1-10, Article 46

2024

Link zum Volltext

Verfügbarkeit prüfen

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e24091-e24091

2023

Link zum Volltext

Verfügbarkeit prüfen

Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer

Clinical breast cancer, 2023-10, Vol.23 (7), p.721-728

2023

Link zum Volltext

Verfügbarkeit prüfen

Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1038-1038

2023

Link zum Volltext

Verfügbarkeit prüfen

Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.611-611

2023

Link zum Volltext

Verfügbarkeit prüfen

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer

Clinical cancer research, 2021-03, Vol.27 (5), p.1361-1370

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor DNA (ctDNA) as a tool to help guide germline testing in patients with solid malignancies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.10602-10602

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS2-11: Ctc-her2+ a novel subset in stage IVaggressive: Molecular correlations, outcome and clinical characteristics in metastatic breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS2-11-PS2-11

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS2-15: The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS2-15-PS2-15

2021

Link zum Volltext

Verfügbarkeit prüfen

ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1057-1057

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-02-05

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-01-04

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-14-05: Emerging molecular variants by circulating tumor DNA after immunotherapy in metastatic breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-14-05

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-02-06: Her2-low ctcs in breast cancer: Pipeline for phenotypic driven, single-cell collection and molecular analysis

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-02-06

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Role of Immunotherapy in Breast Cancer

775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease

Better Reporting Needed for Cosmetics and Women’s Health

Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy

Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease

Landscape of circulating tumour DNA in metastatic breast cancer

Lung Cancer Survival in Patients With Autoimmune Disease

Visual perception training: a prospective cohort trial of a novel, technology-based method to teach melanoma recognition

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors

Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer

Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC)

Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer

Circulating tumor DNA (ctDNA) as a tool to help guide germline testing in patients with solid malignancies

Abstract PS2-11: Ctc-her2+ a novel subset in stage IVaggressive: Molecular correlations, outcome and clinical characteristics in metastatic breast cancer

Abstract PS2-15: The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer

ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC)

Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer

Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer

Abstract P2-14-05: Emerging molecular variants by circulating tumor DNA after immunotherapy in metastatic breast cancer

Abstract P2-02-06: Her2-low ctcs in breast cancer: Pipeline for phenotypic driven, single-cell collection and molecular analysis

Suchergebnisse filtern